000			03261na a2200229 4500
999			_c174 _d174
003			PC174
005			20200323125637.0
008			130622s2013
040			_cH12O
041			_aspa
100			_9501 _aHawkins Carranza, Federico Gustavo _eEndocrinología y Nutrición
100			_aMartínez Díaz-Guerra, Guillermo _9760 _eEndocrinología y Nutrición
245	0	0	_aComparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial _h[artículo]
260			_bJournal of Bone and Mineral Research, _c2013.
300			_a28(6):1355-1368.
500			_aFormato Vancouver: Glüer CC, Marin F, Ringe JD, Hawkins F, Möricke R, Papaioannu N, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Miner Res. 2013;28(6):1355-68.
504			_aContiene 45 referencias, 8 figuras y 4 tablas.
520			_aResumen: Data on treatment of glucocorticoid-induced osteoporosis (GIO) in men are scarce. We performed a randomized, open-label trial in men who have taken glucocorticoids (GC) for 3 months, and had an areal bone mineral density (aBMD) T-score 1.5 standard deviations. Subjects received 20g/d teriparatide (n=45) or 35mg/week risedronate (n=47) for 18 months. Primary objective was to compare lumbar spine (L1L3) BMD measured by quantitative computed tomography (QCT). Secondary outcomes included BMD and microstructure measured by high-resolution QCT (HRQCT) at the 12th thoracic vertebra, biomechanical effects for axial compression, anterior bending, and axial torsion evaluated by finite element (FE) analysis from HRQCT data, aBMD by dual X-ray absorptiometry, biochemical markers, and safety. Computed tomography scans were performed at 0, 6, and 18 months. A mixed model repeated measures analysis was performed to compare changes from baseline between groups. Mean age was 56.3 years. Median GC dose and duration were 8.8mg/d and 6.4 years, respectively; 39.1% of subjects had a prevalent fracture, and 32.6% received prior bisphosphonate treatment. At 18 months, trabecular BMD had significantly increased for both treatments, with significantly greater increases with teriparatide (16.3% versus 3.8%; p=0.004). HRQCT trabecular and cortical variables significantly increased for both treatments with significantly larger improvements for teriparatide for integral and trabecular BMD and bone surface to volume ratio (BS/BV) as a microstructural measure. Vertebral strength increases at 18 months were significant in both groups (teriparatide: 26.0% to 34.0%; risedronate: 4.2% to 6.7%), with significantly higher increases in the teriparatide group for all loading modes (0.005<p<0.015). Adverse events were similar between groups. None of the patients on teriparatide but five (10.6%) on risedronate developed new clinical fractures (p=0.056). In conclusion, in this 18-month trial in men with GIO, teriparatide showed larger improvements in spinal BMD, microstructure, and FE-derived strength than risedronate.
710			_9292 _aServicio de Endocrinología y Nutrición
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc174.pdf _ySolicitar documento
942			_2ddc _cART _n0